GlassScriptPhysician profile
Aaron G Cagle
NPI 1881079283
$4,705.34
in general payments reported to CMS, 2019-2025
36 companies · $790 in 2025
The $790 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,042 · 2022: $985 · 2023: $864 · 2024: $1,024 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $538.22 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $479.92 | 2022-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $379.29 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Antares Pharma, INC. | $328.22 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Novo Nordisk INC | $287.77 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $240.45 | 2021-2025 | |
| Abbott Laboratories | $229.95 | 2022-2025 | Freestyle Libre 3 |
| Collegium Pharmaceutical, INC. | $205.43 | 2021 | |
| Allergan, INC. | $188.02 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $186.70 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $109.90 | 2023-2024 | Yupelri |
| Boston Scientific Corporation | $78.66 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $78.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $59.25 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.04 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.00 | 2022 | |
| Nevro Corp. | $44.91 | 2021 | |
| Tempus Ai, INC | $44.84 | 2024 | |
| Halozyme INC | $38.48 | 2023 | |
| Esperion Therapeutics, INC. | $36.60 | 2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $33.36 | 2021 | |
| Idorsia Pharmaceuticals US INC | $32.88 | 2022-2023 | Quviviq |
| Viatris Specialty LLC | $31.89 | 2025 | Yupelri |
| Scilex Pharmaceuticals INC. | $30.35 | 2021 | |
| Agile Therapeutics, INC. | $24.56 | 2024 | Twirla |
| Daiichi Sankyo INC. | $24.19 | 2022 | |
| Medtronic, INC. | $23.24 | 2023 | Synchromedii |
| Biodelivery Sciences International, INC. | $19.59 | 2021 | |
| Dexcom, INC. | $16.13 | 2022 | |
| Merz Pharmaceuticals, LLC | $15.67 | 2025 | Ampyra, Xeomin, Inbrija |
| Glaxosmithkline, LLC. | $15.58 | 2022 | |
| Tolmar, INC. | $15.46 | 2025 | |
| Galderma Laboratories, L.P. | $14.99 | 2022 | |
| Verity Pharmaceuticals INC. | $14.29 | 2025 | Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Cagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.